FDA Investigator Kurt A Brorson, PhD
Kurt A Brorson, PhD has conducted inspections on 7 sites in 3 countries as of 03 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
7
Last Inspection Date:
03 May 2024
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
Korea (Republic of),
United States of America,
Germany
FDA Investigators that have inspected at least one site in common with Kurt A Brorson, PhD:
Anastasia I Offordile,
Anastasia M Shields,
Anh M Lac,
Anita Narula, PhD,
Anita R Michael,
Ann L Demarco,
Ann Marie Montemurro,
Ashar P Parikh,
Azza Talaat,
Barbara J Holladay,
Barbara Janine Breithaupt,
Bo Chi, PhD,
Brenda W Uratani, PhD,
Byungja E Marciante,
Chaltu Nwakijra,
Charles R Bonapace, PhD,
Chiang Syin, PhD,
Christian D Lynch (CDL),
Christine M Whitby, CSO,
Christopher Downey, PhD,
Concepcion Cruz, Jr,
Craig D Zagata,
Cynthia A Harris, MD, RN,
Cynthia Jim, CSO,
Cynthia White,
Daniel R Azar,
Debra Bower,
Diane L Raccasi,
Doan T Nguyen, PharmD,
Donald C Obenhuber, PhD,
Douglas A Campbell,
Dr. Mark J Seaton, PhD,
Dr. Ralph M Bernstein, PhD,
Dr. Zhihao Qiu (Peter), PhD,
Dr. Zhou Chen (nmi), MD PhD,
Eliezar Ramos,
Emest F Bizjak,
Erika V Butler,
Erin L Mcfiren,
Felix Maldonado,
Gayle S Lawson,
George Pyramides,
Grace I Cortesini,
Hao Kiet D Phan,
Haoheng Yan, PhD,
Hector A Carrero,
Hyung Yul Lee,
Jacek Cieslak, PhD,
Jacqueline Mdiaz Albertini,
James M Mason,
Joan A Loreng,
John D White,
Joseph L Despins, PhD,
Julianne C Mccullough,
Julie D Bringger,
Junho Pak,
Justin A Boyd,
Jyoti B Patel, PhD,
Kalavati Suvarna, PhD,
Kathleen R Jones, PhD,
Kenneth Nieves,
Kevin A Gonzalez,
Ko U Min,
Kristen D Evans,
Kristin M Abaonza,
Kristina J Donohue,
Kristina Mjoyce Pittman,
Lakisha M Williams,
Lynette P Salisbury,
Marcelo O Mangalindan, Jr,
Marea K Harmon,
Mariza M Jafary,
Mark Brunswick, PhD,
Mary E Storch,
Matthew B Casale,
Michael F Skelly, PhD,
Michael Shanks, MS,
Michele M Falchek,
Michelle Yclark Stuart,
Mihaly S Ligmond,
Milos Dokmanovic, PhD,
Monica Commerford, PhD,
Morris Paul,
Mra Munizn,
Nebil A Oumer,
Norman K Starks,
Omotunde O Osunsanmi,
Patricia F Hughes, PhD,
Peter Adams, PhD,
Philip J Snoy,
Prabhu P Raju,
Qing Joanna Zhou, PhD,
Rachel C Harrington,
Reyes Candau Chacon, PhD,
Richard Heath Coats,
Richard Ledwidge (nmi), PhD,
Richard W Berning,
Riley C Myers, PhD,
Robert Jennings,
Robert L Hummel,
Rose Ashley,
Russell J Glapion,
Saleem A Akhtar,
Scott N Lim,
Stephanie L Shapley,
Stephanie Mangigian, MS/OSH, RN,
Steven P Donald,
Stuart W Russell,
Subramanian Muthukkumar, PhD,
Susan M Jackson,
Susan T Hadman,
Thomas E Friel,
Thuy T Nguyen, LCDR,
Toyin B Oladimeji,
Veronica Fuentes, MS,
Virgilio F Pacio, CSO,
Viviana Matta,
Vlada Matusovsky,
Walter N Lange,
Wayne E Seifert,
Yangmin Ning,
Yanming An, PhD,
Zerita White,
Zhong Li, PhD,
Zhongren Wu,
Ziyang Su, PhD
Kurt A Brorson, PhD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| February, 2004 | FDA 483 | Janssen Biotech, Inc. - Form 483, 2004-02-11 |
| March, 2015 | FDA 483 | CELLTRION Inc - Form 483, 2015-03-06 |
| June, 2002 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2002-06-20 |
| September, 2014 | FDA 483 | Janssen Biotech, Inc. - Form 483, 2014-09-24 |
| May, 2004 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2004-10-22 |
| February, 2004 | EIR | Janssen Biotech, Inc. - EIR, 2004-02-11 |
| July, 2012 | FDA 483 | BioReliance Corporation - Form 483, 2012-07-03 |
| March, 2015 | EIR | CELLTRION Inc - EIR, 2015-03-06 |
| May, 2004 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2004-05-28 |
| June, 2002 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2002-06-28 |
| August, 2012 | EIR | WuXi Advanced Therapies Inc. - EIR, 2012-08-24 |
| February, 2004 | FDA 483 Response | Janssen Biotech, Inc. - Form 483R, 2004-03-10 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more